Abstract
The efficacy of immune checkpoint inhibitors (ICIs) in neuroendocrine neoplasms (NEN) has not been fully explored, but recent clinical trials showed the effectiveness of ICIs in high-grade NEN. Despite the importance of tumor-infiltrating lymphocytes (TIL) and PD-L1 expression to ICI treatment outcomes, a comprehensive assessment of these biomarkers has not yet been conducted in NEN. We investigated PD-L1 expression and TIL distributions in NENs using an artificial intelligence (AI)-powered analyzer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
